Immunoclin Corp (IMCL) 3.7500 $IMCL
ImmunoClin Corporation (IMCL) Proudly Announces the Appointment of Molecular Biologist and Virologist, Dr. Marco Kaiser to the Company's Scientific Advisory Board
PR Newswire - Wed Apr 30, 7:20AM CDT
ImmunoClin Corporation (OTCBB: IMCL), is a U.S. healthcare company specializing in personalized medicine using proprietary immunological targets to develop prognostic tests, novel anti-infectious and anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Berlin-based Dr. Marco Kaiser to its Scientific Advisory Board and looks forward to benefitting from Dr. Kaiser's expertise in molecular biology.
Thought Leaders are Optimistic that Emerging Therapies will Offer Efficacy Benefits Over Current Therapies for Metastatic Gastric Cancer; Augmenting Biomarker-Driven Prescribing
PR Newswire - Thu Apr 10, 12:00PM CDT
Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and Roche/Genentech/Chugai's Kadcyla will join Roche/Genentech/Chugai's Herceptin in the HER2-targeted treatment armamentarium for metastatic gastric cancer. Moreover, oncologists express enthusiasm for c-Met overexpression as a predictive biomarker in metastatic gastric cancer, and anticipate that rilotumumab (Amgen/Astellas Pharma) and onartuzumab (Roche/Genentech/Chugai), both in combination with chemotherapy, will demonstrate efficacy advantages over chemotherapy alone. Interviewed physicians also expressed enthusiasm for the angiogenesis inhibitor ramucirumab (Eli Lilly/ImClone Systems), based on positive Phase III data from the REGARD and RAINBOW trials.
Allayo Adds Biotech Industry Veteran to Board of Directors
PRWeb - Fri Mar 28, 9:05AM CDT
Today Allayo announced the addition of a new member to the company board of directors. Allayo, known for their innovative virtual health assistant app which was acclaimed at HealthBeat 2013 as one of the coolest new apps, provides health care consumers with an easier way to understand and act on their personal health information and assistance in arranging for appointments, prescription refills, lab work, and more. The mobile app provides a single point of coordination for personal health that also lets consumers win gifts and rewards for their healthy behaviors.
Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.
Zymeworks Inc. Announces Strategic Collaboration with Lilly Subsidiary ImClone Systems to Develop Bi-specific Antibodies Using Zymeworks' Azymetric(TM) Platform
Business Wire - Thu Jan 09, 3:59AM CST
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric(TM) platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
USA Pharmaceutical Excel Companies Directory
M2 - Tue Dec 03, 2:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/qvqb2j/usa) has announced the addition of the "USA Pharmaceutical Excel Companies Directory" directory to their offering. This is a directory of U.S. Pharmaceuticals companies in Microsoft Excel format. It is searchable, and exportable for use in mailings and lead generation. This database includes the following fields, where available: - Company name - Mailing address - City - State - Zip (easy sorting by geographic region) - Main phone - Fax - Email address (where available) - Website address - Business Sector - Name of Officers with titles There are 1,333 company records, including 1,003 email addresses. When you purchase the Global Company License, everyone in your entire organization, every department and job title, may access this data, making it worth the extra few hundred to invest in the Global License. Companies Mentioned This is a just a sampling of the companies included: - Accugenix - Achaogen - Aciont - Active Motif - ActiveSight - Integrated DNA Technologies Inc - Idun Pharmaceuticals - llsbio LLC - ImClone Systems Inc - Immpheron Inc - Immune Response Corporation - Open Biosystems Inc - Opexa Pharmaceuticals Inc - Oscient Pharmaceuticals - Osel Inc - Synthecon Inc - Synthegen Inc - Syntrix BioSystems - Tapestry Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/qvqb2j/usa About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advaxis Appoints Daniel J. O'Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board
Business Wire - Tue Aug 20, 6:30AM CDT
Advaxis, Inc. (OTCQB:ADXS) ("Advaxis" or the "Company"
, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O'Connor, formerly Executive Vice President, to the position of President and Chief Executive Officer. Mr. O'Connor has also joined the Board of Directors. Dr. James Patton, currently the Chairman of the Audit Committee, has been elected Non-Executive Chairman of the Board. Thomas A. Moore, formerly Chairman and Chief Executive Officer of Advaxis, will continue to serve on the Board of Directors and as a consultant to the Company.
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012
M2 - Tue Aug 13, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jcwjc/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012" report to their offering. 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. Scope - A snapshot of the global therapeutic scenario for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. - A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development - Novartis AG - ImClone Systems Incorporated - Celgene Corporation - Merck KGaA - PCI Biotech Holding ASA - VentiRx Pharmaceuticals, Inc. Drug Profiles - cetuximab - Amphinex Bleomycin - Sym-004 - Erbitux Avastin - saracatinib - everolimus - Gleevec Taxotere - Lenalidomide Cetuximab - Tarceva RAD001 - Cetuximab Lenalidomide - Docetaxel Gemcitabine - VTX-2337 Cetuximab - BYL-719 Cetuximab For more information visit http://www.researchandmarkets.com/research/6j...rrent_head
Head And Neck Carcinoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frzrtb/head_and_neck) has announced the addition of the "Head And Neck Carcinoma - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for head and neck carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for head and neck carcinoma. The data is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for head and neck carcinoma. - A review of the head and neck carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the head and neck carcinoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for head and neck carcinoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding head and neck carcinoma pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction Report Overview Head and Neck Carcinoma Overview Therapeutics Development An Overview of Pipeline Products for Head and Neck Carcinoma Companies Involved in Head and Neck Carcinoma Therapeutics Development Head and Neck Carcinoma - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned: - Celgene Corporation - ImClone Systems Incorporated - Merck KGaA - Novartis AG - PCI Biotech Holding ASA - VentiRx Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/fr...d_and_neck
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]
M2 - Tue Jun 04, 12:38PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhjbwz/biological) has announced the addition of Supplier Relations US, LLC's updated report "Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]" to their offering. This 169-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through March 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. The industry's revenue for the year 2012 was reported at $23.7 billion USD, with an estimated gross profit of 59.01%. Import was valued at $11.0 billion USD from 63 countries. The industry also exported $10.5 billion USD worth of merchandise to 166 cou
Third Rock Ventures Expands and Strengthens Team
Business Wire - Tue May 14, 7:00AM CDT
Third Rock Ventures, LLC, a venture capital firm focused on building healthcare companies, today announced that it has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies, and the overall strategy and direction of the firm.
NYBA "CEO Breakfast Club" Is Brewing Better Biotech in New York
Business Wire - Mon Apr 01, 2:08PM CDT
The New York Biotechnology Association, the voice of New York's bioscience industry, has launched a new roundtable series focused on bringing together New York's bioscience elite with the next generation of entrepreneurs. NYBA's "CEO Breakfast Club" will meet six times throughout the year, with each breakfast headlined by one of New York's bioscience leaders. Each breakfast is limited to only 20 bioscience executives; the exclusive sponsor of the CEO Breakfast Club is BioMed Realty Trust, one of New York's leading bioscience real estate developers.
Morria Biopharmaceuticals Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer
Marketwire - Wed Jan 23, 7:01AM CST
Morria Biopharmaceuticals Plc (the "Company" , an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that Dr. Alan Harris has joined the Company full time as Chief Medical Officer. Dr. Harris was initially recruited to Morria in July 2012 in a part time capacity. He will develop and lead the clinical development programs for Morria's Multi-Functional Anti-Inflammatory Drug candidates including MRX-4 in allergic rhinitis, and MRX-6 in dermatitis.
The Launch of Five Targeted Biologic Therapies Between 2011 and 2021 Will Propel Gastric Cancer Treatment Toward More-Personalized Therapy
Business Wire - Tue Dec 18, 8:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2011 to 2021, the launch of five targeted biologic therapies for gastric cancer will transform a predominantly cytotoxic market in the direction of more personalized treatment. Decision Resources anticipates the launch of two novel next-generation HER2-targeting therapies, Roche/Genentech/Chugai's T-DM1 and Roche/Genentech/Chugai's Perjeta; two c-Met inhibitors, Roche/Genentech/Chugai's MetMAb and Amgen's rilotumumab; and an anti-angiogenesis vascular endothelial growth factor receptor-2 inhibitor, Eli Lilly/ImClone Systems' ramucirumab. In 2021, these agents (combined) will hold 53 percent market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
ImmunoClin Corporation (IMCL) Proudly Announces the Appointment of Molecular Biologist and Virologist, Dr. Marco Kaiser to the Company's Scientific Advisory Board
PR Newswire - Wed Apr 30, 7:20AM CDT
ImmunoClin Corporation (OTCBB: IMCL), is a U.S. healthcare company specializing in personalized medicine using proprietary immunological targets to develop prognostic tests, novel anti-infectious and anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Berlin-based Dr. Marco Kaiser to its Scientific Advisory Board and looks forward to benefitting from Dr. Kaiser's expertise in molecular biology.
Thought Leaders are Optimistic that Emerging Therapies will Offer Efficacy Benefits Over Current Therapies for Metastatic Gastric Cancer; Augmenting Biomarker-Driven Prescribing
PR Newswire - Thu Apr 10, 12:00PM CDT
Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and Roche/Genentech/Chugai's Kadcyla will join Roche/Genentech/Chugai's Herceptin in the HER2-targeted treatment armamentarium for metastatic gastric cancer. Moreover, oncologists express enthusiasm for c-Met overexpression as a predictive biomarker in metastatic gastric cancer, and anticipate that rilotumumab (Amgen/Astellas Pharma) and onartuzumab (Roche/Genentech/Chugai), both in combination with chemotherapy, will demonstrate efficacy advantages over chemotherapy alone. Interviewed physicians also expressed enthusiasm for the angiogenesis inhibitor ramucirumab (Eli Lilly/ImClone Systems), based on positive Phase III data from the REGARD and RAINBOW trials.
Allayo Adds Biotech Industry Veteran to Board of Directors
PRWeb - Fri Mar 28, 9:05AM CDT
Today Allayo announced the addition of a new member to the company board of directors. Allayo, known for their innovative virtual health assistant app which was acclaimed at HealthBeat 2013 as one of the coolest new apps, provides health care consumers with an easier way to understand and act on their personal health information and assistance in arranging for appointments, prescription refills, lab work, and more. The mobile app provides a single point of coordination for personal health that also lets consumers win gifts and rewards for their healthy behaviors.
Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.
Zymeworks Inc. Announces Strategic Collaboration with Lilly Subsidiary ImClone Systems to Develop Bi-specific Antibodies Using Zymeworks' Azymetric(TM) Platform
Business Wire - Thu Jan 09, 3:59AM CST
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric(TM) platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
USA Pharmaceutical Excel Companies Directory
M2 - Tue Dec 03, 2:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/qvqb2j/usa) has announced the addition of the "USA Pharmaceutical Excel Companies Directory" directory to their offering. This is a directory of U.S. Pharmaceuticals companies in Microsoft Excel format. It is searchable, and exportable for use in mailings and lead generation. This database includes the following fields, where available: - Company name - Mailing address - City - State - Zip (easy sorting by geographic region) - Main phone - Fax - Email address (where available) - Website address - Business Sector - Name of Officers with titles There are 1,333 company records, including 1,003 email addresses. When you purchase the Global Company License, everyone in your entire organization, every department and job title, may access this data, making it worth the extra few hundred to invest in the Global License. Companies Mentioned This is a just a sampling of the companies included: - Accugenix - Achaogen - Aciont - Active Motif - ActiveSight - Integrated DNA Technologies Inc - Idun Pharmaceuticals - llsbio LLC - ImClone Systems Inc - Immpheron Inc - Immune Response Corporation - Open Biosystems Inc - Opexa Pharmaceuticals Inc - Oscient Pharmaceuticals - Osel Inc - Synthecon Inc - Synthegen Inc - Syntrix BioSystems - Tapestry Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/qvqb2j/usa About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advaxis Appoints Daniel J. O'Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board
Business Wire - Tue Aug 20, 6:30AM CDT
Advaxis, Inc. (OTCQB:ADXS) ("Advaxis" or the "Company"
, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O'Connor, formerly Executive Vice President, to the position of President and Chief Executive Officer. Mr. O'Connor has also joined the Board of Directors. Dr. James Patton, currently the Chairman of the Audit Committee, has been elected Non-Executive Chairman of the Board. Thomas A. Moore, formerly Chairman and Chief Executive Officer of Advaxis, will continue to serve on the Board of Directors and as a consultant to the Company. Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012
M2 - Tue Aug 13, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jcwjc/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012" report to their offering. 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. Scope - A snapshot of the global therapeutic scenario for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. - A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development - Novartis AG - ImClone Systems Incorporated - Celgene Corporation - Merck KGaA - PCI Biotech Holding ASA - VentiRx Pharmaceuticals, Inc. Drug Profiles - cetuximab - Amphinex Bleomycin - Sym-004 - Erbitux Avastin - saracatinib - everolimus - Gleevec Taxotere - Lenalidomide Cetuximab - Tarceva RAD001 - Cetuximab Lenalidomide - Docetaxel Gemcitabine - VTX-2337 Cetuximab - BYL-719 Cetuximab For more information visit http://www.researchandmarkets.com/research/6j...rrent_head
Head And Neck Carcinoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frzrtb/head_and_neck) has announced the addition of the "Head And Neck Carcinoma - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for head and neck carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for head and neck carcinoma. The data is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for head and neck carcinoma. - A review of the head and neck carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the head and neck carcinoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for head and neck carcinoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding head and neck carcinoma pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction Report Overview Head and Neck Carcinoma Overview Therapeutics Development An Overview of Pipeline Products for Head and Neck Carcinoma Companies Involved in Head and Neck Carcinoma Therapeutics Development Head and Neck Carcinoma - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned: - Celgene Corporation - ImClone Systems Incorporated - Merck KGaA - Novartis AG - PCI Biotech Holding ASA - VentiRx Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/fr...d_and_neck
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]
M2 - Tue Jun 04, 12:38PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhjbwz/biological) has announced the addition of Supplier Relations US, LLC's updated report "Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]" to their offering. This 169-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through March 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. The industry's revenue for the year 2012 was reported at $23.7 billion USD, with an estimated gross profit of 59.01%. Import was valued at $11.0 billion USD from 63 countries. The industry also exported $10.5 billion USD worth of merchandise to 166 cou
Third Rock Ventures Expands and Strengthens Team
Business Wire - Tue May 14, 7:00AM CDT
Third Rock Ventures, LLC, a venture capital firm focused on building healthcare companies, today announced that it has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies, and the overall strategy and direction of the firm.
NYBA "CEO Breakfast Club" Is Brewing Better Biotech in New York
Business Wire - Mon Apr 01, 2:08PM CDT
The New York Biotechnology Association, the voice of New York's bioscience industry, has launched a new roundtable series focused on bringing together New York's bioscience elite with the next generation of entrepreneurs. NYBA's "CEO Breakfast Club" will meet six times throughout the year, with each breakfast headlined by one of New York's bioscience leaders. Each breakfast is limited to only 20 bioscience executives; the exclusive sponsor of the CEO Breakfast Club is BioMed Realty Trust, one of New York's leading bioscience real estate developers.
Morria Biopharmaceuticals Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer
Marketwire - Wed Jan 23, 7:01AM CST
Morria Biopharmaceuticals Plc (the "Company"
, an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that Dr. Alan Harris has joined the Company full time as Chief Medical Officer. Dr. Harris was initially recruited to Morria in July 2012 in a part time capacity. He will develop and lead the clinical development programs for Morria's Multi-Functional Anti-Inflammatory Drug candidates including MRX-4 in allergic rhinitis, and MRX-6 in dermatitis. The Launch of Five Targeted Biologic Therapies Between 2011 and 2021 Will Propel Gastric Cancer Treatment Toward More-Personalized Therapy
Business Wire - Tue Dec 18, 8:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2011 to 2021, the launch of five targeted biologic therapies for gastric cancer will transform a predominantly cytotoxic market in the direction of more personalized treatment. Decision Resources anticipates the launch of two novel next-generation HER2-targeting therapies, Roche/Genentech/Chugai's T-DM1 and Roche/Genentech/Chugai's Perjeta; two c-Met inhibitors, Roche/Genentech/Chugai's MetMAb and Amgen's rilotumumab; and an anti-angiogenesis vascular endothelial growth factor receptor-2 inhibitor, Eli Lilly/ImClone Systems' ramucirumab. In 2021, these agents (combined) will hold 53 percent market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
